Low-dose integrated chemoimmunohormonotherapy with cisplatin, subcutaneous interleukin-2, α-interferon and tamoxifen for advanced metastatic melanoma - A pilot study

Melanoma Research

Volumn 6, Issue 3, 1996, Pages 257-265

  Bernengo, M G ^a   Doveil, G C ^a   Bertero, M ^a   Quaglino, P ^a   Fierro, M T ^a   Savoia, P ^a   Appino, A ^a   Colonna, S ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Chemotherapy; Cisplatin; Immunophenotyping; Immunotherapy; Interleukin 2 therapeutic use; Melanoma therapy; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; CD16 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CISPLATIN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HYPOTENSION; IMMUNOPHENOTYPING; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PILOT PROJECTS; RECURRENCE; SKIN NEOPLASMS; TAMOXIFEN; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0029902042     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199606000-00009     Document Type: Article

References (39)

1. Legha SS. Current therapy for malignant melanoma. Semin Oncol 1989, 16, Suppl 1: 34-44.
2. Cocconi G, Bella M, Calabresi F et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992; 327: 516-523.
3. Garbe C. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 1993; 3: 291-299.
4. Del Prete SA, Maurer LH, O'Donnell J et al. Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984; 68: 1403-1405.
5. McClay EF, Mastrangelo MJ, Bellet RE et al. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 1987; 71: 465-469.
6. McClay EF, Mastrangelo MJ, Sprandio JD et al. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989; 63: 1292-1295.
7. Fierro MT, Bertero M, Novelli M et al. Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen. Melanoma Res 1993; 3: 127-131.
8. Lattanzi SC, Tosteson T, Chertoff J et al. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 1995; 5: 365-369.
9. Rosenberg SA, Lotze MT, Yang JC et al. Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474-485.
10. Rosenberg S, Yang J, Topalian S et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994; 271: 907-912.
11. Sparano J, Fisher R, Sunderland M et al. Randomized phase III trial of treatment with high-dose interleukin-2 alone or in combination with interferon alpha-2a in patients with advanced melanoma. J Clin Oncol 1993; 11: 1969-1977.
12. Lichtenstein AK, Pende D. Enhancement of natural killer cytotoxicity by cisdiaminedichloroplatinum in vivo and in vitro. Cancer Res 1986; 46: 639-644.
13. Allavena P, Pirovano P, Bonazzi C et al. In vitro and in vivo effects of cisplatin on the generation of lymphokine activated killer cells. J Natl Cancer Inst 1990; 82: 132-139.
14. Garbe C, Kreuser E, Zouboulis C et al. Combined treatment of metastatic melanoma with interferons and cytotoxic drugs. Semin Oncol 1992; 19: 63-69.
15. Smol M, Longo D. Chemotherapy drug interactions with biological agents. Semin Oncol 1993; 20: 80-93.
16. Bajetta E, Negretti E, Giannotti B et al. Phase II study of interferon α-2a and dacarbazine in advanced melanoma. Am J Clin Oncol. 1990; 13: 405-409.
17. Bajetta E, Di Leo A, Zampino MG et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alpha-2a in the treatment of advanced melanoma. J Clin Oncol 1994; 12: 806-811.
18. Buzaid AC, Legha SS. Combination of chemotherapy with interleukin-2 and interferon-alpha for the treatment of advanced melanoma. Semin Oncol 1994; 21, Suppl 14: 23-28.
19. Khayat D, Borel C, Tourani JM et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon-alpha 2a for metastatic melanoma. J Clin Oncol 1993; 11: 2173-2180.
20. Khayat D, Antoine E, Rixe O et al. Chemoimmunotherapy of metastatic malignant melanoma. The Salpétrière Hospital (SOMPS) experience. Eur J Cancer 1993; 29: S2-S5.
21. Borel CH, Rixe O, Barthier S et al. Results of three consecutive studies on 111 metastatic melanoma (MM) patients treated by Chemoimmunotherapy with cisplatin, interleukin-2 interferon-α (abstract). Fifth International Congress on Anti-cancer Chemotherapy, Paris, 31 January-3 February 1995.
22. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
23. Mulé JJ, Shu S, Rosenberg SA. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo. J Immunol 1985; 135: 646-652.
24. Lindemann A, Hermann F, Oster W et al. Lymphokine activated killer cells. Blut 1989; 59: 375-384.
25. Wiebke EA, Rosenberg SA, Lotze MT. Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. J Clin Oncol 1988; 6: 1440-1449.
26. Atzpodien J, Lopez-Hänninen E, Kirchner H et al. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 1995; 31: 876-881.
27. Von Rohr A, Ghosh AK, Thatcher N et al. Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy. Br J Cancer 1993; 67: 163-171.
28. Castello G, Cornelia P, Manzo T et al. Immunological and clinical effects of intramuscular rIFNα-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma. Melanoma Res 1993; 3: 43-49.
29. Schneekloth C, Körfer A, Hadam M et al. Low-dose interleukin-2 in combination with interferon-α effectively modulates biological response in vivo. Acta Haematol 1993; 89: 13-21.
30. Lindemann A, Brossart P, Höffken K et al. Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase IB study. Cancer Immunot Immunother 1993; 37: 307-315.
31. Meropol NJ, Porter M, Perez RP et al. Low dose interleukin-2 (IL-2): daily subcutaneous injection results in selective in vivo expansion of natural killer (NK) cells with minimal toxicity (abstract). ASCO Proc 1994 no. 965.
32. Walewski J, Paietta E, Dutcher J et al. Evaluation of natural killer and lymphokine-activated (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous. J Cancer Res Clin Oncol 1989; 115: 170-174.
33. Lemont JF, Azzaria M, Gros P. Increased mar gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells. Cancer Res 1988; 48: 6348-6353.
34. Mann SP, Andrews DA, Howell SB. Modulation of cisplatin accumulation by forskolin in human ovarian carcinoma cells. Proc Am Assoc Cancer Res 1989; 30: 531-532.
35. Cohen JHM, Danel L, Cordier G et al. Sex steroid receptors in peripheral T cells: absence of androgen receptors and restriction of estrogen receptors to OKT8-positive cells. J Immunol 1983; 131: 2767-2771.
36. Parmiani G, Anichini A, Fossati G. Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? J Natl Cancer Inst 1990; 82: 361-370.
37. Van den Berg HW, Leahey WJ, Lynch M et al. Recombinant human interferon-α increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen. Br J Cancer 1987; 55: 255-257.
38. Buzaid AC, Murren JR, Durivage HJ. High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma. Cancer 1991; 68: 1238-1241.
39. Mohammed MQ, Photiou A, Shah P et al. Activity of platinum drugs against melanoma cell lines: is it modulated in vitro in the presence of tamoxifen? Anticancer Res 1995; 15: 1319-1326.